Core Insights - Nautilus Biotechnology, Inc. is participating in multiple investor conferences to enhance visibility and engagement with investors [1][4] Company Overview - Nautilus Biotechnology is a development stage life sciences company headquartered in Seattle, Washington, with R&D operations in San Carlos, California [3] - The company focuses on creating a platform technology for quantifying and analyzing the complexity of the proteome, aiming to democratize access to proteomics and advance human health and medicine [3] Upcoming Events - Management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8 at 10:50 a.m. Pacific Time [4] - A presentation is scheduled for the Q3 Investor Summit Group Virtual Conference on September 16 at 10:00 a.m. Pacific Time, followed by 1x1 meetings on September 17 [4]

Core Insights - Seer, Inc. will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York, highlighting its role in the healthcare sector [1] - The management will engage in a fireside chat on September 9, 2025, providing an opportunity for investors to gain insights into the company's operations [2] Company Overview - Seer, Inc. is a leader in deep, unbiased proteomics, offering insights with unprecedented scale, speed, precision, and reproducibility [3] - The Proteograph Product Suite integrates proprietary engineered nanoparticles, streamlined automation, optimized consumables, and advanced analytical software to address challenges faced by traditional proteomic methods [3] - Seer's technology overcomes limitations of conventional proteomics, such as inconsistent data and limited throughput, enabling the discovery of biological insights [3]

Summary of Cytek Biosciences (CTKB) Conference Call Industry Overview - The conference focused on advancements in proteomics and cellular research, highlighting the importance of new technologies in these fields [2][3]. Key Companies Discussed - **Cytek Biosciences**: A life science tool company specializing in flow cytometry technology [6]. - **Quantum SI**: A company offering next-generation protein sequencing technology [3]. Core Points and Arguments Technological Advancements - **Quantum SI's Technology**: Introduces next-generation protein sequencing that allows for the study of single amino acid variants and post-translational modifications, which are crucial for understanding disease progression and therapy responses [3][4]. - **Cytek's Full Spectrum Technology**: Enhances flow cytometry by capturing all signals from cells, allowing for the detection of more parameters and improving sensitivity, particularly in cancer studies [6][7][8]. Market Dynamics - **Demand for New Applications**: Both companies noted a shift in customer needs towards more complex studies that traditional technologies could not address [4][5]. - **Challenges in Adoption**: New technologies face skepticism regarding their accuracy and applicability, necessitating proof of concept through data generation in leading research centers [10][11]. Business Management in a Challenging Market - **Financial Resilience**: Quantum SI highlighted its strong balance sheet, allowing it to maintain strategic investments despite market challenges [16][18]. - **Flow Cytometry Market**: Cytek emphasized the ongoing need for flow cytometers in labs, with many existing units nearing replacement, presenting an opportunity for growth [19][20][21]. Replacement Opportunities - **Market Size**: There are approximately 50,000 flow cytometers in use, with many due for replacement, creating a significant market opportunity [22]. - **Key Factors for Replacement**: New technology performance, backward compatibility, and overall cost reduction are critical for capturing replacement opportunities [23][24]. Clinical Market Progress - **Geographic Expansion**: Cytek has received clinical approvals in China and is progressing in Europe, with plans to navigate the more complex FDA approval process in the U.S. [27][28][29]. Future Pipeline and Innovations - **Quantum SI's Proteus Platform**: Expected to launch in 2026, this platform will significantly enhance sequencing capabilities, allowing for more complex sample analysis [36][39]. - **AI Integration**: Both companies are leveraging AI to improve operational efficiency and enhance product capabilities, with Quantum SI focusing on proprietary data to train AI models for better performance [40][41][45]. Additional Important Insights - **Market Disruption**: Cytek views competition as an opportunity to solidify its market leadership, especially in light of disruptions from competitors [25][26]. - **Revenue Growth**: Cytek's revenue growth has outpaced instrument sales, indicating a strong service and reagent business [26]. This summary encapsulates the key discussions and insights from the conference, highlighting the advancements in proteomics and flow cytometry, market dynamics, and future opportunities for both Cytek Biosciences and Quantum SI.

Summary of Quantum-Si (QSI) Conference - August 14, 2025 Industry and Company Overview - **Industry**: Proteomics and Cellular Research - **Companies Involved**: Quantum-Si (QSI) and Cytec Biosciences Key Points and Arguments Quantum-Si's Technology and Applications - Quantum-Si offers next-generation protein sequencing, enabling the reading of individual amino acids, which allows for the study of previously difficult-to-analyze proteins and variants [3][4] - Customers are interested in applications such as single amino acid variants, isomers, and post-translational modifications, which are crucial for understanding therapy responses and disease progression [4] - The U.S. market shows a demand for advanced proteomics tools, while international markets may focus more on basic protein characterization due to limited access [5] Cytec Biosciences' Flow Cytometry Innovations - Cytec specializes in flow cytometry, enhancing conventional technology with full spectrum profiling, which captures more data and improves sensitivity in applications like minimal residual disease (MRD) detection [6][8] - The technology allows for faster drug discovery by enabling the analysis of multiple parameters quickly, addressing the needs of the pharmaceutical industry [9] Market Challenges and Business Management - The academic market is facing challenges, but Quantum-Si maintains a strong balance sheet that allows for strategic investments and operational stability through 2028 [16][17] - Cytec aims to replace older flow cytometers, leveraging the need for advanced features and cost efficiency to capture market opportunities despite tight capital expenditures [19][20] Clinical Market and Regulatory Approvals - Cytec has achieved clinical approvals in China and is progressing in Europe, with tools approved for applications like leukemia and MRD [28][29] - The U.S. FDA approval process is ongoing, which is expected to take longer compared to other regions [30] Future Technology and Market Potential - Quantum-Si is developing a new platform called Proteus, expected to launch in 2026, which will significantly increase sequencing capacity and capabilities [37][40] - The company believes that as technology improves and costs decrease, the adoption of proteomics will mirror the growth seen in DNA sequencing [31][34] Role of AI in Operations and Product Development - Both companies are integrating AI to enhance data analysis and operational efficiency, with Cytec using AI for panel design and Quantum-Si leveraging AI for protein design and analysis [41][42][46] - Quantum-Si has partnered with NVIDIA to improve AI-driven design processes, resulting in significant improvements in amino acid coverage [46][47] Additional Important Insights - The proteomics market is complex, with varying costs and applications, making it difficult to establish a uniform business model [35] - The companies are focused on maintaining their strategic direction and leveraging their technological advancements to capture market share and drive growth [18][21]

Core Insights - Seer, Inc. reported a 32% year-over-year revenue growth, reaching $4.1 million for Q2 2025, driven by increased product sales and service revenue [4][6] - The company launched the high-throughput Proteograph ONE assay and SP200 automation instrument, enhancing scalability and efficiency [3][9] - Seer aims to transform deep, unbiased proteomics, with its technology now supporting multiple population-scale studies [3] Financial Performance - Revenue for Q2 2025 was $4.1 million, up from $3.1 million in Q2 2024, with product revenue at $2.7 million and service revenue at $1.2 million [4][6] - Gross profit was $2.1 million, resulting in a gross margin of 52% for the quarter [5] - Operating expenses decreased by 21% to $22.6 million, primarily due to a reduction in stock-based compensation [5] Net Loss and Cash Position - The net loss for Q2 2025 was $19.4 million, an improvement from a net loss of $22.9 million in the same period last year [6] - As of June 30, 2025, the company had approximately $263.3 million in cash, cash equivalents, and investments [6][9] Future Guidance - Seer expects full-year 2025 revenue to be between $17 million and $18 million, indicating a 24% growth at the midpoint compared to 2024 [7] Recent Developments - The company announced a collaboration with Korea University for a 20,000-sample population-scale proteomics study using the Proteograph ONE assay [9] - Seer has accelerated third-party validation through impactful data presentations and publications from key opinion leaders at recent conferences [9]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $591,000, significantly below expectations, primarily due to a near halt in capital sales of new instruments [7][24] - Gross profit was $351,000, resulting in a gross margin of 59% for the quarter [24] - For the six months ended June 30, 2025, total revenue was $1,400,000, with a gross profit of $837,000 and a gross margin of 58% [25] Business Line Data and Key Metrics Changes - Capital sales of new instruments were the main driver for the revenue decline, while consumable purchases slightly exceeded expectations [7][8] - The installed base of customers is approximately 65% outside the U.S. and 35% within the U.S., encompassing various customer types including academic, industrial, and government research labs [35] Market Data and Key Metrics Changes - The U.S. academic labs experienced a significant slowdown in capital purchases due to NIH funding uncertainties [7][29] - Despite capital market headwinds, consumable purchasing remained consistent across market segments, with government and pharma/biotech accounts showing stable demand [68] Company Strategy and Development Direction - The company aims to accelerate commercial adoption, deliver on its innovation roadmap, and preserve financial strength [6][21] - New instrument acquisition options have been launched to address capital sales headwinds, allowing customers to purchase consumables without upfront capital investment [10][11] - The company remains confident in the long-term market opportunity in proteomics and is focused on growing its installed customer base [11][21] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the impact of NIH funding uncertainties on capital sales and expressed optimism about the potential for growth through new acquisition models [29][30] - The company anticipates that the new models will help capture consumable revenue and improve overall financial performance in the long term [29][70] Other Important Information - The company reported total operating expenses of $30,500,000 for Q2 2025, an increase from $26,800,000 in Q2 2024, while adjusted operating expenses were $23,800,000, slightly down from $24,400,000 [26] - The company ended the quarter with $214,200,000 in cash, cash equivalents, and investments in marketable securities, providing a strong financial position [27][32] Q&A Session Summary Question: How much of the $591,000 revenue is overseas and in pharma/biotech? - The company does not break out revenue by specific segments but noted that 65% of its installed base is outside the U.S. and 35% is within [35] Question: Is $500,000 to $600,000 the bottom for revenue? - Management expressed optimism that this is the bottom and expects gradual improvement, though not instant [36][38] Question: What does a typical placement look like under the new model? - The company offers several models, including capital purchases, reagent rentals, and short-term placements based on consumable revenue potential [40] Question: Are there any trends in leads with the new acquisition opportunities? - Initial data suggests that customers who were previously interested but constrained by capital are now engaging with the new options [46][49] Question: Will Proteus be offered through new models? - Currently, there are no plans to offer Proteus through alternative models; the focus remains on capital sales [61] Question: How is consumable purchasing trending? - Consumable revenue was slightly ahead of expectations, with consistent purchasing across market segments despite capital sales challenges [68] Question: Are the new kits suitable for specific end markets? - The new kits are designed to meet the needs of pharma/biotech customers and are expected to enhance penetration in that segment [72] Question: Is the company considering partnerships or acquisitions given its cash position? - While the company is open to exploring opportunities, the primary focus remains on executing its core technology and business [80][81] Question: If revenue remains soft, where would cuts be made? - The company does not anticipate cuts in the commercial team but will remain targeted in its approach to R&D and operational expenses [85][90]

Q2 2025 Financial Performance - Illumina's Q2 2025 revenue reached $1.06 billion, a decrease of 3% year-over-year (YoY) on both a constant currency (CC) and reported basis[7] - The non-GAAP operating margin for Q2 2025 was 23.8%[7] - Non-GAAP diluted earnings per share (EPS) for Q2 2025 stood at $1.19[7] Regional Revenue Performance - Americas region generated $586 million in revenue, a decrease of 5% YoY CC and 6% YoY reported[7] - Europe's revenue was $310 million, an increase of 6% YoY CC and 7% YoY reported[7] - Asia Pacific, Middle East, and Africa (AMEA) region contributed $100 million, a decrease of 14% YoY CC and 15% YoY reported[7] - Greater China's revenue was $63 million, a decrease of 14% YoY CC and 15% YoY reported[7] NovaSeq X Transition - NovaSeq X accounted for over 50% of high-throughput (HT) revenue and over 75% of HT Gigabases (Gb) shipped in Q2 2025[22] - NovaSeq X consumables revenue is targeted to represent approximately 50% of HT revenue by the end of 2025[22] - NovaSeq X is targeted to represent approximately 75% of HT Gb shipped towards the end of 2025[22] Acquisition of SomaLogic - Illumina announced the acquisition of SomaLogic for $350 million in cash, payable at closing, with up to $75 million in near-term revenue performance-based milestones and potential performance-based royalties[15] - The acquisition is projected to close in the first half of 2026, pending regulatory clearance[14] - SomaLogic is expected to become profitable in 2027 on a non-GAAP operating income basis, with non-GAAP operating margins aligning with Illumina's in 2028[15] Financial Guidance - Illumina's FY25 revenue guidance indicates a growth of 0% to 2%, with an FX benefit of approximately 20 bps for the rest of the world, and a revenue between $190 million and $210 million for Greater China[35] - Q3 2025 revenue guidance indicates a decline of 2.5% to 1.5%, with an FX benefit of approximately 60 bps, implying a reported revenue of $1.06 billion to $1.07 billion[35]

Company Participation - Seer, Inc. will participate in the Canaccord Genuity 45 Annual Growth Conference in Boston, MA [1] - The management is scheduled for a fireside chat on August 13 at 9:00 a.m. Eastern Time [2] Company Overview - Seer, Inc. is a pioneer in deep, unbiased proteomics, providing insights with unprecedented scale, speed, precision, and reproducibility [3] - The Proteograph Product Suite integrates proprietary engineered nanoparticles, streamlined automation, optimized consumables, and advanced analytical software [3] - Seer's technology addresses challenges faced by traditional proteomic methods, which often struggle with inconsistent data and limited throughput [3]

Core Insights - Nautilus Biotechnology, Inc. reported significant advancements in its proteome analysis platform during Q2 2025, including the publication of a scientific manuscript showcasing novel data generated by its technology [2][3] - The company signed collaborations with major research institutes to utilize its platform for studying Tau proteoforms in relation to Alzheimer's disease, aiming to enhance understanding of disease-relevant biology [3] Financial Performance - Operating expenses for Q2 2025 were $17.1 million, an 18% decrease from $20.8 million in the same period last year, attributed to cost optimization and reduced salaries and professional services [4] - The net loss for Q2 2025 was $15.0 million, compared to a net loss of $18.0 million in the prior year [5] - As of June 30, 2025, the company had cash, cash equivalents, and investments totaling $179.5 million [5] Research and Development - The company continues to focus on both targeted and broadscale proteomic development efforts, demonstrating the effectiveness of its Iterative Mapping method for measuring proteoforms [2] - The collaborations with research institutes are expected to facilitate fundamental advances in understanding Alzheimer's disease progression [3]

Core Viewpoint - Nautilus Biotechnology, Inc. is set to report its financial results for the second quarter of 2025 on July 31, 2025, before market opening [1]. Group 1: Financial Reporting - The financial results will be announced before the market opens on July 31, 2025 [1]. - A conference call will be held at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss the results and business developments [2]. Group 2: Company Overview - Nautilus Biotechnology is a development stage life sciences company headquartered in Seattle, Washington, with R&D operations in San Carlos, California [3]. - The company focuses on creating a platform technology for quantifying the proteome, aiming to democratize access to proteomics and advance human health and medicine [3].